ATE374622T1 - Genetische impstoffe mit adjuvans - Google Patents

Genetische impstoffe mit adjuvans

Info

Publication number: ATE374622T1
Authority: AT; Austria
Prior art keywords: adjuvans; genetic vaccines; inducing; nucleic acid; methods
Prior art date: 1999-11-03

Application number

AT99956885T

Other languages

English (en)

Inventor

Joel Haynes

Georg Widera

James Fuller

Timothy Shipley

Deborah Fuller

Mary Wu

Original Assignee

Powderject Vaccines Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-03

Filing date

1999-11-03

Publication date

2007-10-15

1999-11-03 Application filed by Powderject Vaccines Inc filed Critical Powderject Vaccines Inc

2007-10-15 Application granted granted Critical

2007-10-15 Publication of ATE374622T1 publication Critical patent/ATE374622T1/de

Links

230000002068 genetic effect Effects 0.000 title abstract 2
229960005486 vaccine Drugs 0.000 title abstract 2
239000002671 adjuvant Substances 0.000 title 1
238000000034 method Methods 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
239000003153 chemical reaction reagent Substances 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
230000003053 immunization Effects 0.000 abstract 1
238000002649 immunization Methods 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Immunology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Pulmonology (AREA)
Transplantation (AREA)
AIDS & HIV (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)

AT99956885T 1999-11-03 1999-11-03 Genetische impstoffe mit adjuvans ATE374622T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US1999/025854 WO2001032208A1 (en)	1999-11-03	1999-11-03	Adjuvanted genetic vaccines

Publications (1)

Publication Number	Publication Date
ATE374622T1 true ATE374622T1 (de)	2007-10-15

Family

ID=22273970

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99956885T ATE374622T1 (de)	1999-11-03	1999-11-03	Genetische impstoffe mit adjuvans

Country Status (14)

Country	Link
EP (1)	EP1227840B1 (de)
JP (1)	JP2003516936A (de)
CN (1)	CN100333794C (de)
AT (1)	ATE374622T1 (de)
AU (1)	AU780448C (de)
CA (1)	CA2389686A1 (de)
CY (1)	CY1107845T1 (de)
DE (1)	DE69937258T2 (de)
DK (1)	DK1227840T3 (de)
ES (2)	ES2294864T3 (de)
IL (2)	IL149415A0 (de)
NZ (1)	NZ518766A (de)
PT (2)	PT1913957E (de)
WO (1)	WO2001032208A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE460945T1 (de) *	1999-11-03	2010-04-15	Powderject Vaccines Inc	Genetische adjuvanz-impfstoffe
EP1392357A2 (de) *	2001-05-18	2004-03-03	Powderject Vaccines, Inc.	Impfstoffzusamensetzung
US7566478B2 (en)	2001-07-25	2009-07-28	Nantero, Inc.	Methods of making carbon nanotube films, layers, fabrics, ribbons, elements and articles
CN103372217B (zh) *	2012-04-28	2014-12-10	中国科学院深圳先进技术研究院	聚合物纳米载体制剂及其制备方法和应用
WO2014145906A2 (en) *	2013-03-15	2014-09-18	Phd Preventative Health Care And Diagnostics, Inc.	A prefilled medication device, method of making and using the same
EP3983085A4 (de)	2019-06-12	2023-01-25	Wisconsin Alumni Research Foundation	Neuartiges adjuvans für tierische und menschliche impfstoffe

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5925362A (en) *	1993-08-11	1999-07-20	Jenner Technologies	Method to elicit an antitumor response with human prostate-specific antigen
EP1293559B1 (de) *	1994-01-21	2005-07-27	Powderject Vaccines, Inc.	Gasbetätigtes Element zum Austragen von Genmaterial
US5739118A (en) *	1994-04-01	1998-04-14	Apollon, Inc.	Compositions and methods for delivery of genetic material
ES2301175T3 (es) *	1996-02-09	2008-06-16	Smithkline Beecham Biologicals S.A.	Vacunas contra el producto del gen 63 del virus de la varicela zoster.
DE69828182T2 (de) *	1997-02-14	2005-12-22	Merck & Co., Inc.	Polynukleotid-impfstoff-formulierungen
AU6897098A (en) *	1997-04-14	1998-11-11	University Of Massachusetts Medical Center	Saponin adjuvants in combination with dna vaccination
CN1285753A (zh) *	1997-12-02	2001-02-28	鲍德杰克特疫苗公司	透皮给药微粒疫苗组合物
GB9818627D0 (en) *	1998-08-26	1998-10-21	Glaxo Group Ltd	Improvements in dva vaccination
CU22740A1 (es) *	1998-09-07	2002-02-28	Ct Ingenieria Genetica Biotech	Formulación de ácidos nucleicos y acemanano

1999
- 1999-11-03 ES ES99956885T patent/ES2294864T3/es not_active Expired - Lifetime
- 1999-11-03 ES ES07015414T patent/ES2340617T3/es not_active Expired - Lifetime
- 1999-11-03 IL IL14941599A patent/IL149415A0/xx unknown
- 1999-11-03 AT AT99956885T patent/ATE374622T1/de not_active IP Right Cessation
- 1999-11-03 AU AU13399/00A patent/AU780448C/en not_active Ceased
- 1999-11-03 DE DE69937258T patent/DE69937258T2/de not_active Expired - Lifetime
- 1999-11-03 DK DK99956885T patent/DK1227840T3/da active
- 1999-11-03 EP EP99956885A patent/EP1227840B1/de not_active Expired - Lifetime
- 1999-11-03 WO PCT/US1999/025854 patent/WO2001032208A1/en not_active Ceased
- 1999-11-03 JP JP2001534412A patent/JP2003516936A/ja active Pending
- 1999-11-03 CA CA002389686A patent/CA2389686A1/en not_active Abandoned
- 1999-11-03 PT PT07015414T patent/PT1913957E/pt unknown
- 1999-11-03 CN CNB998170399A patent/CN100333794C/zh not_active Expired - Fee Related
- 1999-11-03 PT PT99956885T patent/PT1227840E/pt unknown
- 1999-11-03 NZ NZ518766A patent/NZ518766A/en not_active IP Right Cessation
2002
- 2002-04-30 IL IL149415A patent/IL149415A/en not_active IP Right Cessation
2008
- 2008-01-02 CY CY20081100004T patent/CY1107845T1/el unknown

Also Published As

Publication number	Publication date
ES2294864T3 (es)	2008-04-01
AU780448C (en)	2006-02-23
DK1227840T3 (da)	2008-02-04
IL149415A0 (en)	2002-11-10
CN100333794C (zh)	2007-08-29
DE69937258T2 (de)	2008-07-03
EP1227840A1 (de)	2002-08-07
JP2003516936A (ja)	2003-05-20
DE69937258D1 (de)	2007-11-15
AU780448B2 (en)	2005-03-24
CA2389686A1 (en)	2001-05-10
AU1339900A (en)	2001-05-14
PT1227840E (pt)	2008-01-09
PT1913957E (pt)	2010-05-05
EP1227840B1 (de)	2007-10-03
CN1426309A (zh)	2003-06-25
IL149415A (en)	2008-11-03
NZ518766A (en)	2005-07-29
WO2001032208A1 (en)	2001-05-10
CY1107845T1 (el)	2013-06-19
ES2340617T3 (es)	2010-06-07

Legal Events

Date

Code

Title

Description

2008-03-15

UEP

Publication of translation of european patent specification

Ref document number: 1227840

Country of ref document: EP

2011-08-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
PT1487485E (pt)	2011-03-11	Adjuvantes de imidazoquinolina para vacinas de adn
DK1459766T3 (da)	2008-10-13	Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
ATE315405T1 (de)	2006-02-15	Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
DE60228758D1 (de)	2008-10-16	Immunisierung gegen chlamydia tracheomatis
CY1121353T1 (el)	2020-05-29	Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
NZ540544A (en)	2007-08-31	Nucleic acids and proteins from streptococcus groups A & B
WO2002061113A3 (en)	2002-12-12	Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
BRPI0418317A (pt)	2007-05-02	vacina de aumento de crescimento à base de epitopo de neutralização
CY1110585T1 (el)	2015-04-29	ΣΥΣΚΕΥΑΣΙΑ (ΠΑΚΕΤΑΡΙΣΜΑ) ΑΝΟΣΟΔΙΕΓΕΡΤIΚΩΝ CpG ΕΝΤΟΣ ΟΜΟΙΑΖΟΝΤΩΝ ΜΕ ΙΟ ΣΩΜΑΤΙΩΝ: ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΚΑΙ ΧΡΗΣΗ
ATE269100T1 (de)	2004-07-15	Verfahren zur therapeutischen impfung
IS4518A (is)	1999-01-10	Nýtt lyfjaform fyrir bóluefni
AU1013601A (en)	2001-05-08	Method of inducing and/or enhancing an immune response to tumor antigens
DE60144201D1 (de)	2011-04-21	Lawsonia intracellularis Impfstoff
ATA155598A (de)	2001-06-15	Neue influenzavirus-impfstoffzusammensetzung
CY1107845T1 (el)	2013-06-19	Γενετικα εμβολια με ανοσοενισχυτικο
ATE370745T1 (de)	2007-09-15	Verbesserte polysaccharid- und glykokonjugat- vakzine
WO2009074861A3 (en)	2009-12-17	Improved vaccine
WO1999053960A3 (en)	1999-12-23	Enhancing immune responses to genetic immunization by using a chemokine
ATE319833T1 (de)	2006-03-15	Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus
DK1272652T3 (da)	2005-02-14	Herpesvirus til immunmodulation
NO20020615D0 (no)	2002-02-08	Vaksine
DE60239753D1 (de)	2011-05-26	Impfstoff gegen infektiöses lachsanämievirus
DE69922212D1 (de)	2004-12-30	Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
ATE460945T1 (de)	2010-04-15	Genetische adjuvanz-impfstoffe
EP1502602A3 (de)	2006-05-17	Verfahren zur therapeutischen Impfung